Skip to main content

Table 2 Characteristics of patients receiving a second-line treatment for advanced NSCLC in the pre– and post–I-O periods

From: Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

  PreI-O
(1 January 2010–31 March 2016)
PostI-O
(1 April 2016–30 June 2019)
All (N = 690)a NSQ (n = 500) SQ (n = 87) All (N = 326)b NSQ (n = 243) SQ (n = 57)
Age,c years
Median
Q1–Q3
Range
65
57–72
29–91
65
56.5–72.5
29–91
66
62–72
39–80
66
59–73
31–90
65
58–73
31–90
70
64–72
43–84
Female, n (%) 380 (55.1) 296 (59.2) 36 (41.4) 177 (54.3) 148 (60.9) 16 (28.1)
Initial TNM stage, n (%)
I–IIIAd 66 (9.6) 36 (7.2) 17 (19.5) 38 (11.7) 22 (9.1) 15 (26.3)
IIIB 86 (12.5) 59 (11.8) 19 (21.8) 38 (11.7) 21 (8.6) 14 (24.6)
IV 538 (78.0) 405 (81.0) 51 (58.6) 250 (76.7) 200 (82.3) 28 (49.1)
Location of metastases, n (%)
Visceral, excl. adrenal/liver 164 (23.8) 132 (26.4) 12 (13.8) 77 (23.6) 63 (25.9) 9 (15.8)
Bone 94 (13.6) 80 (16.0) 6 (6.9) 50 (15.3) 43 (17.7)  < 5
Liver 47 (6.8) 35 (7.0)  < 5 16 (4.9) 13 (5.3)  < 5
Brain 44 (6.4) 39 (7.8)  < 5 39 (12.0) 34 (14.0)  < 5
Lymph 39 (5.7) 26 (5.2) 7 (8.0) 21 (6.4) 15 (6.2)  < 5
Adrenal 25 (3.6) 17 (3.4)  < 5 13 (4.0) 13 (5.3) 0 (0.0)
CCI, n (%)
0 234 (33.9) 171 (34.2) 25 (28.7) 108 (33.1) 89 (36.6) 14 (24.6)
1 165 (23.9) 118 (23.6) 30 (34.5) 72 (22.1) 50 (20.6) 19 (33.3)
2 69 (10.0) 47 (9.4) 14 (16.1) 27 (8.3) 18 (7.4) 6 (10.5)
3 91 (13.2) 68 (13.6) 8 (9.2) 39 (12.0) 26 (10.7) 11 (19.3)
4 +  131 (19.0) 96 (19.2) 10 (11.5) 80 (24.5) 60 (24.7) 7 (12.3)
First-line treatment, n (%)
Platinum-based chemotherapy 491 (71.2) 331 (66.2) 77 (88.5) 189 (58.0) 123 (50.6) 46 (80.7)
Tyrosine kinase inhibitor 154 (22.3) 141 (28.2)  < 5 104 (31.9) 100 (41.2)  < 5
Non-platinum chemotherapy 38 (5.5) 23 (4.6) 7 (8.0) 5 (1.5)  < 5  < 5
I-O therapy  < 5  < 5 0 (0.0) 27 (8.3) 16 (6.6) 7 (12.3)
Other monoclonal antibodies 6 (0.9)  < 5  < 5  < 5 0 (0.0)  < 5
Duration of first-line treatment, n (%)
 < 1 month 136 (19.7) 78 (15.6) 27 (31.0) 41 (12.6) 20 (8.2) 15 (26.3)
1– < 3 months 328 (47.5) 228 (45.6) 54 (62.1) 132 (40.5) 90 (37.0) 34 (59.6)
3– < 6 months 103 (14.9) 84 (16.8)  < 5 71 (21.8) 60 (24.7) 6 (10.5)
6– < 12 months 61 (8.8) 53 (10.6)  < 5 49 (15.0) 44 (18.1)  < 5
 ≥ 12 months 62 (9.0) 57 (11.4)  < 5 32 (9.8) 28 (11.5)  < 5
Unknown 0 (0.0) 0 (0.0) 0 (0.0)  < 5  < 5 0 (0.0)
  1. Unless otherwise indicated, all characteristics were recorded at time of diagnosis. Data were masked when patient numbers for an individual category were greater than zero but less than 5
  2. Abbreviations: CCI Charlson Comorbidity Index; I-O immuno-oncology; NOS not otherwise specified; NSCLC non-small cell lung cancer; NSQ non-squamous; Q quartile; SQ squamous; TNM tumor, nodes, metastasis
  3. aPatients had NSQ (n = 500), SQ (n = 87), NOS (n = 93) or Other (n = 10) histology
  4. bPatients had NSQ (n = 243), SQ (n = 57), NOS (n = 25) or Other (n =  < 5) histology
  5. cAge recorded at start of second-line treatment for advanced NSCLC
  6. dPatients with TNM stage I–IIIA NSCLC at diagnosis represent “progressed patients” who subsequently received systemic anticancer therapy during the study period (see Additional file 1)